The Future of Nanooncology

A special issue of Nanomaterials (ISSN 2079-4991). This special issue belongs to the section "Biology and Medicines".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 318

Special Issue Editors


E-Mail Website1 Website2
Guest Editor
Department of Pharmaceutical Sciences, College of Pharmacy-Glendale, Midwestern University, Glendale, AZ, USA
Interests: medicinal chemistry; drug design; structure activity relationships; computational drug design; epitranscriptomics; post-translational protein modification; antibody engineering; antibody and nanoparticle drug conjugates

Special Issue Information

Dear Colleagues,

According to the WHO, cancer causes almost one in six deaths. Among the most common are breast, lung, colon and rectal and prostate cancer. Although many new anticancer agents can be found on the market, an interesting direction in the fight against cancer is represented by nanomaterials. These include nanodiagnostics or engineered nanomaterials with intrinsic anticancer activity or, in addition, drug delivery nanosystems that encapsulate anticancer drugs and modify their pharmacokinetics and pharmacodynamics. Moreover, regarding targeted and controlled delivery, drug delivery nanosystems can also enhance the effect of drugs and help to overcome drug resistance in cancer cells.

This Special Issue "The Future of Nano-Oncology" of Nanomaterials aims to highlight the latest discoveries and advances in all areas of science related to nanomaterials and their potential applications in the fight against cancer. This Special Issue is particularly focused on the design, development and testing of nanodiagnostics and nanomaterials with anticancer activity, as well as various nanosystems for drug delivery. Reviews, research articles and short communications on this topic are invited from research groups around the world to support the dissemination of scientific knowledge through this open access journal. Scientists/physicians that have tested these bioactive nanoagents/nanomaterials in preclinical or clinical trials are also encouraged to publish their recent findings in this Special Issue of Nanomaterials.

Prof. Dr. Josef Jampilek
Dr. Mark Olsen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanoparticles
  • nanomaterials
  • biocompatible materials
  • coating
  • drug delivery
  • antitumor agents
  • antineoplastic activity
  • tissue engineering
  • regenerative medicine
  • diagnostics

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop